Visual Universitätsmedizin Mainz

Dr. Yong Ook Kim

Dr. Yong Ook Kim ist Postdoktorand am TIM. Er promovierte 2006 in Biotechnologie an der Yonsei Universität in Seoul, Korea und sammelte Erfahrungen als Postdoktorand im Bereich der Pharmakologie – hauptsächlich in vorklinischen Studien, am Korea Research Institute of Bioscience & Biotechnology (KRIBB) in Seoul. An der University of Massachusetts Amherst in den USA entwickelte er sein Interesse für Stoffwechselkrankheiten , die durch Fettleibigkeit und Diabetes verursacht werden. Er schloss sich 2010 Prof. Schuppans Labor an der Harvard Medical School in Boston an und folgte später seinem Ruf nach Mainz.

Sein Forschungsschwerpunkt sind entzündliche und fibrosiende Lebererkrankungen,  das Leberkarzinom und die nichtalkoholische Fettlebererkrankung  in Zusammenarbeit mit mehreren Forschungsgruppen. Dies umfasst die 1) Entwicklung von non-invasiven Diagnostika für Fibroseentwicklung, 2) Validierung von potentiellen anti-entzündlichen und anti-fibrotischen Pharmaka in Mausmodellen  und transgenen Tieren, 3) Untersuchung der pathogenetischen Rolle der Matrix Metalloproteinasen in der Fibroseprogression und -regression, 4) Entwicklung verlässlicher Mausmodelle der nicht-alkoholischen Steatohepatitis (NASH) und neuer  Kurzzeitmodelle des hepatozellularen Karzinoms, u.a. um neue Medikamente zu testen und pathogenetische Mechanismen aufzuklären.

Er leitet ein kleines Fibroseforschungsteam und kollaboriert mit verschiedenen Partnern in Fibroseprojekten anderer Organe wie Haut (Sklerodermie) und Lunge. Er kooperiert auch mit der Universität Groningen in der Entwicklung und Validierung der Klutur von „precision cut liver slices“, welche in Zukunft wahrscheinlich Tierexerimente einsparen können.

 

Originalpublikationen

  1. Yoshida S, Ikenaga N, Liu SB, Peng ZW, Chung J, Sverdlov DY, Miyamoto M, Kim YO, Ogawa S, Arch RH, Schuppan D, Popov Y, 2014., Extra-hepatic PDGFB, Delivered by Platelets, Promotes Activation of Hepatic Stellate Cells and Biliary Fibrosis in Mice, Gastroenterology 2014;27. doi: 10.1053/j.gastro.2014.08.038.

     

  2. Schuppan D, Kim YO. Evolving therapies for liver fibrosis, J Clin Invest 2013;1;123(5):1887-901.

     

  3. Schattenberg JM, Nagel M, Kim YO, Kohl T, Wörns MA, Zimmermann T, Schad A, Longerich T, Schuppan D, He YW, Galle PR, Schuchmann M. Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP, Am J Physiol-Gastr L 2012;15;303(4):G498-506.

     

  4. Kim YO, Schuppan D, When GLP-1 hits the liver: a novel approach for insulin resistance and NASH, Am J Physiol-Gastr L 2012;15;302(8):G759-61.

     

  5. Park HW, Kim YO, Ha JS, Youn SH, Kim HH, Bilgrami AL, Shin CS. Effects of associated bacteria on the pathogenicity and reproduction of the insect-parasitic nematode Rhabditis blumi (Nematoda: Rhabditida), Can J  Microbiol 2011;57(9):750-8.

     

  6. Kim HS, Kim JY, Ryu HS, Shin BR, Kang JS, Kim HM, Kim YO, Hong JT, Kim Y, Han SB. Phenotypic and functional maturation of dendritic cells induced by polysaccharide isolated from Paecilomyces cicada, J Med Food 2011;14(0):1-10.

     

  7. Kim YO, Cho KW, Andrade JE, Burgess JR, Kim Y-C. Dietary naringenin increases hepatic peroxisome proliferators-activated receptor alpha (PPARα) protein expression and decreases plasma triglyceride and adiposity in rats, Eur J Nutr 2010;50(2): 81-8.

     

  8. Kim HS, Kim JY, Ryu HS, Park HG, Kim YO, Kang JS, Kim HM, Hong JT, Kim Y, Han SB. Induction of dendritic cell maturation by beta-glucan isolated from Sparassis crispa, Int Immunopharmacol 2010;10(10): 1284-94.

     

  9. Kim YM, Choi NS, Kim YO, Son DH, Chang YH, Song JJ, Kim JS. Expression and characterization of a covel deoxyribose 5-phosphate aldolase from Paenibacillus sp. EA001, J Microbiol Biotechnol 2010;20(6): 995-1000.

     

  10. Kim HS, Kim JY, Kang JS, Kim HM, Kim YO, Hong IP, Lee MK, Hong JT, Kim Y, Han SB. Cordlan polysaccharide isolated from mushroom Cordyceps militaris induces dendritic cell maturation through toll-like receptor 4 signalings, Food Chem Toxicol 2010;48:1926-1933.

     

  11. Kim JH, Kim YO, Jeon J, Choi D, Shin CS. L-Trp and L-Leu-OEt derivatives of the Monascus pigment exert high anti-obesity effects on mice, Biosci Biotech Biochem 2010;74(2): 304-308.

     

  12. Kim YM, Chang YH, Choi NS, Kim YO, Song JJ, Kim JS. Cloning, expression, and characterization of a new deoxyribose 5-phosphate aldolase from Yersinia sp. EA015, Protein Expres Purif 2009;68(2):196-200.

     

  13. Jeon J, Jung H, Kim JH, Kim YO, Youn SH, Shin CS. Effect of the monascus pigment threonine derivative on regulation of the cholesterol level in mice, Food Chem 2008;107:1078-1085.

     

  14. YI Y, Park HW, Shrestha S, Seo J, Kim YO, Shin CS, Kim Y. Identification of Two Entomopathogenic Bacteria from a Nematode Pathogenic to the Oriental Beetle, Blitopertha orientalis, J Microbiol Biotechnol 2007;17(6):968-978.

     

  15. Kim YO, Park HW, Kim JH, Lee JY, Moon SH, Shin CS. Anti-cancer effect and structural characterization of endo-polysaccharide from cultivated mycelia of Inonotus obliquus, Life Sciences 2006;79:72-80.

     

  16. Kim JH, Kim HJ, Kim C, Jung H, Kim YO, Ju JY, Shin CS. Development of lipase inhibitors from various derivatives of monascus pigment produced by Monascus Fermentation, Food Chem 2006;101:357-364.

     

  17. Kim YO, Han SB, Lee HW, Ahn HJ, Yoon YD, Jung JK, Kim HM, Shin CS, Immuno-stimulating effect of the endo-polysaccharide produced by submerged culture of Inonotus obliquus, Life Sciences 2005;77:2438-2456.

     

  18. Kim C, Jung H, Kim YO, Shin CS, Anti-microbial activities of amino acid derivatives of Monascus pigment, FEMS Microbiol Lett 2006;264:117-124.

     

Kürzlich veröffentlichte Abstracts

  1. Kim YO, Surabattula R, Park K-S, Weng S-Y, Schuppan D. A diet-induced mouse model with development of severe NASH, Hepatology 2014;58:S1 143A-143A.

     

  2. Karnik S, Kim Y-O, Nash M, Sulfab M, Zeng D, Zhong H, Robson SC, Schuppan D, Tumas D. Antifibrotic and Anti-inflammatory Activity of the Adenosine Receptor 2b Antagonist, GS-6201, in Murine Models of Primary Sclerosing Cholangitis, Hepatology 2014;58:S1 122A-122A.

     

  3. Wang X-Y, Weng S-Y, Kim YO, Klein T, Schuppan D. Linaglipton mediated DPP-4 inhibition ameliorates inflammation and fibrosis in models of NASH and biliary fibrosis, Hepatology 2014;58:S1 122A-122A.

     

  4. Weng S-Y, Vijayan S, Wang X-Y, Padberg K, Kim YO, Frank B, Schuppan D. Alternative regulation of macrophages activation by IL-4 receptor alpha in fibrosis progression and reversal, Hepatology 2014;58:S1 123A-123A.

     

  5. Weng S-Y, Wang X-Y, Vijayan S, Padberg K, Kim YO, Crosby JR, McCaleb ML, Schuppan D. Pharmacological modulation of IL-4Ralpha regulates liver fibrosis progression and regression by tuning M2 macrophage polarization, Hepatology 2014;58:S1 123A-123A.

     

  6. Wang X-Y, Weng S-Y, Kim YO, Klein T, Schuppan D. Long-acting glucagon-like peptide-1 receptor agonism mitigates inflammation and fibrosis in model of NASH and biliary fibrosis, Journal of Hepatology 2014; 60(S1): S150–S151.

     

  7. Weng S-Y, Padberg K, Kim YO, Wang X-Y, Frank B, Schuppan D. The role of IL-4 receptor alpha in alternative macrophage activation and during fibrosis progression and reversal, Journal of Hepatology 2014; 60(S1): S280.

     

  8. Weng S-Y, Padberg K, Wang X-Y, Kim YO, Crosby JR, McCaleb ML, Schuppan D. Regulation of liver fibrosis by tuning M2 macrophage polarization through IL-4Rα inhibition, Journal of Hepatology 2014; 60(S1): S279–S280.

     

  9. Kim YO, Stoll M, Weng S-Y, Park K-S, Hebich B, Heck R, Popov Y, Hamdi S, Schuppan D. Lack of Matrix metalloproteinase-8 ameliorates liver fibrosis progression and promotes fibrosis regression, Hepatology 2013; 58: S1 580A-580A.

     

  10. Weng S-Y, Padberg K, Kim YO, Wang X-Y, Frank B, Schuppan D. IL-4 receptor alpha1 regulates M2 macrophage signaling and is an important modulator of liver fibrosis progression and regression, Hepatology 2013; 58: S1 309A-309A.

     

  11. Calvent CJ, Sehgal A, Kim YO, Schuppan D. Inhibition of the progression of biliary and panlobular fibrosis in vivo by C12-200-siProcollagen alpha 1(I) RNA in lipid-like carriers, Hepatology 2013; 58: S1 582A-583A.

     

  12. Weng S-Y, Padberg K, Kim YO, Wang X-Y, McCaleb ML, Crosby JR, Schuppan D. Differential regulation of liver fibrosis progression and regression by pharmacological inhibition of M2 macrophage polarization through IL-4Ralpha1, Hepatology 2013; 58: S1 577A-577A.

     

  13. Wang X-Y, Weng S-Y, Klein T, Kim YO, Schuppan D. A long-acting GLP-1 agonist exenatide suppresses inflammation and fibrosis in models of NASH and biliary fibrosis, Hepatology 2013; 58: S1 585A-586A.

     

  14. Kuehle B, Biwer U, Kim YO, Schuppan D, Ross T. Synthesis and radiolabeling with Ga-68 of an alpha(v)beta(6)-ligand for liver fibrosis imaging, Journal of Labelled Compounds & Radiopharmaceuticals 2013; 56:S S429-S429.

     

  15. Calvente C, Diken M, Sehgal A, Kim YO, Schuppan D. Specific in vivo delivery of procollagen a1(I) siRNA in lipid-like carriers inhibits the progression of billiary liver fibrosis, Journal of Hepatology 2013; 58: S S236.

     

  16. Weng S-Y, Padberg K, Kim YO, Wang XY, McCaleb M, Schuppan D. Modulation of liver fibrosis by regulating alternatively activated macrophage signaling through IL-4Ralpha, Journal of Hepatology 2013; 58: S S150–S151.

     

  17. Kim YO, Stoll M, Weng S-Y, Hebich B, Resa T, Heck R, Park K-S, Biwer U, Schuppan D. Effect of matrix metalloproteinase-8 deficiency on liver fibrosis progression and regression, Journal of Hepatology 2013; 58: S S457.

     

  18. Resa T, Kim YO, Stoll M, Hebich B, Robson S, Schuppan D. Effect of adenosine 2B receptor antagonist MRS1754 on fibrosis progression and regression in mice, Journal of Hepatology 2013; 58: S S461.

     

  19. Wang X, Klein T, Kim YO, Schuppan D. Anti-inflammatory and direct antifibrotic effect of the oral hepatotropic DPPIV inhibitor linagliptin in a model of biliary fibrosis and NASH, Journal of Hepatology 2013; 58: S S527-S528.

     

  20. Kim YO, Stoll M, Hebich B, Park KS, Heck R, Schuppan D. Liver fibrosis progression and regression in matrix metalloproteinase-8 deficient mice, Zeitschrift für Gastroenterologie 2013; 51: K172.

     

  21. Wang XY, Weng SY, Klein T, Kim YO, Schuppan D. Anti-inflammatory and direct antifibrotic effect of the oral hepatotropic DPP4 inhibitor Linagliptin in model of bilary fibrosis and NASH, Zeitschrift für Gastroenterologie 2013; 51: K174.

     

  22. Weng SY, Padberg K, Kim YO, Wang XY, Mccaleb M, Schuppan D. Regulation of liver fibrosis by tuning M2 macrophage signaling through IL-4Ralpha, Zeitschrift für Gastroenterologie 2013; 51: K171.